SAN JOSE, Calif., Oct. 28, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced the appointment of Emanuele
Ostuni, Ph.D. to its Scientific Advisory Board.
Dr. Ostuni is Head of Europe
for Cell and Gene Therapies at Novartis Oncology, where he oversees
all commercialization aspects of the division's portfolio in
Europe, including Kymriah, the
first FDA-approved CAR-T cell therapy. Dr. Ostuni has been
with Novartis since 2012 in various executive roles.
Previously he held positions with Nano
Terra, McKinsey & Co., and Surface Logix. Dr. Ostuni was
also the co-founder of Enumeral Biomedical and served on its board
of directors through its public listing in 2014. Dr. Ostuni
earned a Ph.D. in Physical Chemistry from Harvard University and a bachelor's and master's
degree in Chemistry from Georgetown
University.
"We are pleased to have such an accomplished and experienced
leader in the cell therapy field join our Scientific Advisory
Board," stated Amit Kumar, Ph.D.,
Chief Executive Officer of Anixa. "Anixa seeks to add
relevant expertise to its advisory board as we near the beginning
of clinical trials for our products, including our CAR-T therapy
for ovarian cancer, which is partnered with the Moffit Cancer
Center and the Wistar Institute. Dr. Ostuni's experience in
CAR-T cell therapy development, partnering and commercialization
will be invaluable to us as we move our therapy forward."
"I look forward to working with Anixa's broad portfolio of
technologies, given its potential to improve the lives of many
cancer patients, and in particular its CAR-T approach for treating
solid tumors," commented Dr. Ostuni. "I am excited to offer
my experience and expertise to advance this novel approach through
the clinical process and, should the data prove favorable, enable
the millions of women diagnosed with ovarian cancer the opportunity
to benefit from this potentially groundbreaking therapy."
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Anixa contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Tiberend Strategic Advisors, Inc.
Sharen Tilman (Investors)
stilman@tiberend.com
646-604-5149
Johanna Bennett (Media)
jbennett@tiberend.com
212-375-2686
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-names-novartis-executive-dr-emanuele-ostuni-to-scientific-advisory-board-300945852.html
SOURCE Anixa Biosciences, Inc.